title: Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.
abstract: OBJECTIVE
  We analyzed data from the placebo arm of the MTOPS trial to determine clinical predictors of BPH progression.
  
  
  METHODS
  A total of 3,047 patients with LUTS were randomized to either placebo, doxazosin (4 to 8 mg), finasteride (5 mg), or a combination of doxazosin and finasteride. Average length of followup was 4.5 years. The primary outcome was time to overall clinical progression of BPH, defined as either a confirmed 4-point or greater increase in AUA SS, acute urinary retention, incontinence, renal insufficiency, or recurrent urinary tract infection. We analyzed BPH progression event data from the 737 men who were randomized to placebo.
  
  
  RESULTS
  The rate of overall clinical progression of BPH events in the placebo group was 4.5 per 100 person-years, for a cumulative incidence (among men who had at least 4 years of followup data) of 17%. The risk of BPH progression was significantly greater in patients on placebo with a baseline TPV of 31 ml or greater vs less than 31 ml (p <0.0001), a baseline PSA of 1.6 ng/dl or greater vs PSA less than 1.6 ng/dl (p = 0.0009), a baseline Qmax of less than 10.6 ml per second vs 10.6 ml per second or greater (p = 0.011), a baseline PVR of 39 ml or greater vs less than 39 ml (p = 0.0008) and baseline age 62 years or older vs younger than 62 years (p = 0.0002).
  
  
  CONCLUSIONS
  Among men in the placebo arm, baseline TPV, PSA, Qmax, PVR and age were important predictors of the risk of clinical progression of BPH.
authors.affiliation: University of Colorado Health Sciences Center, Aurora, Colorado, USA. david.crawford@uchsc.edu
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
authors.forename: Shandra S
authors.initials: SS
authors.lastname: Wilson
authors.forename: John D
authors.initials: JD
authors.lastname: McConnell
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Slawin
authors.forename: Michael C
authors.initials: MC
authors.lastname: Lieber
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Smith
authors.forename: Alan G
authors.initials: AG
authors.lastname: Meehan
authors.forename: Oliver M
authors.initials: OM
authors.lastname: Bautista
authors.forename: William R
authors.initials: WR
authors.lastname: Noble
authors.forename: John W
authors.initials: JW
authors.lastname: Kusek
authors.forename: Leroy M
authors.initials: LM
authors.lastname: Nyberg
authors.forename: Claus G
authors.initials: CG
authors.lastname: Roehrborn
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D018450:Disease Progression; D017292:Doxazosin / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D015990:Placebo Effect; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D018120:Finasteride; D017292:Doxazosin